Hologic price target raised to $105 from $95 at JPMorgan

JPMorgan raised the firm’s price target on Hologic to $105 from $95 and keeps an Overweight rating on the shares. The company reported another strong quarter, which downs out the "minor noise on messy comps," the analyst tells investors in a research note.